Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double‐blind placebo‐controlled crossover trial. Issue 20 (15th July 2015)

• Record Type: Journal Article
• Authors: Lund Rasmussen, Charlotte; Klee Olsen, Marc; Thit Johnsen, Anna; Aagaard Petersen, Morten; Lindholm, Helena; Andersen, Line; Villadsen, Birgit; Groenvold, Mogens; Pedersen, Lise
• Is Part Of: Cancer. Volume 121:Issue 20(2015)
• Page Start: 3727
• Page End: 3736
• Publication Date: 2015-07-15
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.29563
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29563-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Patients with advanced cancer often experience fatigue and other symptoms that negatively impact their quality of life. The current trial investigated the effect of melatonin on fatigue and other symptoms in patients with advanced cancer.</p> </sec> <sec id="cncr29563-sec-0002" sec-type="section"> <title>METHODS</title> <p>Patients who were aged ≥18 years, had a histologically confirmed stage IV cancer (TNM Classification), and who reported feeling significantly tired were recruited from the palliative care unit at the study institution. The study was a double‐blind, randomized, placebo‐controlled crossover trial. Patients received 1 week of melatonin at a dose of 20 mg or a placebo orally each night, before crossing over and receiving the opposite treatment for 1 week. Between the 2 periods, a washout period of 2 days was implemented. Outcomes were measured using the Multidimensional Fatigue Inventory (MFI‐20) and The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Physical fatigue from the MFI‐20 was the primary outcome. The primary analysis was a complete complier analysis (ie, it included only those patients who had consumed at least 5 capsules per week and who had answered the MFI‐20 on days 1, 7, 10, and 17). Sensitivity analysis using multiple imputations including all randomized patients and all patients completing the intervention were conducted.</p> </sec> <sec id="cncr29563-sec-0003" sec-type="section"> <title>RESULTS</title> <p>A total of 72 patients were randomized. Fifty patients completed the intervention and 44 patients were complete compliers. No significant differences between the placebo and melatonin periods were found for physical fatigue, secondary outcomes, or explorative outcomes.</p> </sec> <sec id="cncr29563-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>In the current study, oral melatonin at a dose of 20 mg was not found to improve fatigue or other symptoms in patients with advanced cancer. <bold><italic>Cancer</italic> 2015;121:3727–3736</bold>. © <italic>2015 American Cancer Society</italic>.</p> </sec> </abstract>